Chan CK, Vanhoutte PM. Secretoneurin facilitates endotheliumdependent relaxations in porcine coronary arteries. Am J Physiol Heart Circ Physiol 300: H1159 -H1165, 2011. First published February 4, 2011 doi:10.1152/ajpheart.00519.2010.-Secretoneurin enhances the adhesion and transendothelial migration properties of monocytes and is a part of the peptide family encoded by the secretogranin II gene. The expression of the secretogranin II gene is upregulated in senescent endothelium. The present study was designed to examine the effects of secretoneurin on endotheliumdependent responsiveness. Isometric tension was measured in rings (with or without endothelium) of porcine coronary arteries. Secretoneurin did not induce contraction of quiescent or contracted rings. In preparations contracted by U-46619, relaxation was observed with high concentrations of the peptide. This relaxation was endothelium dependent and reduced by the nitric oxide synthase inhibitor N -nitro-L-arginine methyl ester (L-NAME). It was abolished when the preparations were incubated with L-NAME in combination with the cyclooxygenase inhibitor indomethacin. The relaxation was not affected by the combination of 1-[(2-chlorophenyl)diphenylmethyl]-1H-pyrazole (TRAM-34) and 6,12,19,20,25,26-hexahydro-5,27:13,18:21,24-trietheno-11,7-etheno-7H-dibenzo[b,m] [1, 5, 12, 16] tetraazacyclotricosine-5,13-diiumditrifluoroacetate hydrate (UCL 1684), which abrogates endothelium-dependent hyperpolarizations. These results indicate that secretoneurin acutely induces relaxation through the activation of endothelial nitric oxide synthase (eNOS) and cyclooxygenase, with nitric oxide playing the dominant role. Prolonged (24 h) incubation with physiological concentrations of secretoneurin enhanced the relaxations to bradykinin and to the calcium ionophore A-23187, but this difference was not observed in preparations incubated with L-NAME or the calmodulin antagonist calmidazolium. Under these conditions, the relaxation to sodium nitroprusside remained unchanged. Incubation with secretoneurin significantly augmented the expression of eNOS and calmodulin as well as the dimerization of eNOS in cultures of porcine coronary arterial endothelial cells. These observations suggest that secretoneurin not only acutely causes but also, upon prolonged exposure, enhances endotheliumdependent relaxations. nitric oxide; secretogranin II ENDOTHELIUM-DEPENDENT, instantaneous decreases in vascular tone (7a) are mediated by nitric oxide in large arteries in response to increased shear stress and other stimuli. Nitric oxide also prevents smooth muscle proliferation as well as platelet aggregation (32, 33) . Under normal conditions, endothelium-derived nitric oxide is produced by the endothelial isoform of nitric oxide synthase (eNOS) (1). Endothelial cells also contain cyclooxygenase(s) transforming arachidonic acid into endoperoxides, which are metabolized further into vasoactive prostanoids, in particular, the vasodilator prostacyclin (21).
nitric oxide; secretogranin II ENDOTHELIUM-DEPENDENT, instantaneous decreases in vascular tone (7a) are mediated by nitric oxide in large arteries in response to increased shear stress and other stimuli. Nitric oxide also prevents smooth muscle proliferation as well as platelet aggregation (32, 33) . Under normal conditions, endothelium-derived nitric oxide is produced by the endothelial isoform of nitric oxide synthase (eNOS) (1) . Endothelial cells also contain cyclooxygenase(s) transforming arachidonic acid into endoperoxides, which are metabolized further into vasoactive prostanoids, in particular, the vasodilator prostacyclin (21) .
In senescent cultured porcine coronary arterial endothelial cells (PCAECs), the presence of eNOS is reduced, whereas the expression of the secretogranin II gene is upregulated 48 times compared with that of cells at first passage (17) . This gene encodes several peptides including secretogranin, EM66, LF19, manserin, and AM5 (5) . Of those, secretoneurin [a 33 amino acid-long, acidic, amphipathic, and heat-stable peptide (5) with high homology in birds, reptiles, fishes, as well as in mammals (18, 22) ] has been intensively studied in relation to endothelial function. It reduces tight junctions between human endothelial cells, hence increasing their permeability (34) . It also promotes the transendothelial migration of monocytes and leukocytes (12) and the adhesion of the former to the endothelium. Secretoneurin can also act as a cytokine that directly stimulates angiogenesis both in vitro and in vivo (13, 14) . Its potency to induce angiogenesis is comparable with that of vascular endothelial growth factor in the mouse cornea (14) . Secretoneurin also prevents serum-starved human umbilical vein endothelial cells to undergo apoptosis and stimulates their proliferation in vitro (14) .
The conjunction of the proinflammatory and proangiogenic effects of secretoneurin (12) (13) (14) 34) concur to suggest an impact on endothelial function. Therefore, the present study was designed to test the hypothesis that secretoneurin modulates the ability of endothelial cells to release mediators causing endothelium-dependent changes in vascular tone.
MATERIALS AND METHODS

Tissue Preparation
Porcine hearts were collected from the local abattoir and immersed in Krebs-Ringer bicarbonate buffer of the following composition: (in mM) 120 NaCl, 25 NaHCO 3, 5.5 glucose, 4.76 KCl, 1.18 MgSO4· 7H2O, 1.18 NaH2PO4 ·2H2O, and 1.25 CaCl2 ·2H2O (control solution). The conduit part and the first branches from the porcine coronary artery were isolated with the fat and connective tissue of the adventitia removed. The arteries were cut into rings (ϳ3 mm in length) for the recording of isometric tension. In some preparations, the endothelium was mechanically removed (7a, 30a) by inserting the tip of a small forceps into the lumen and rolling the preparation on tissue paper soaked in control solution.
Isometric Tension Recording
Rings of arteries were equilibrated for 1 h in organ chambers containing control solution aerated with 95% O 2-5% CO2 and maintained at 37°C. They were connected to force transducers (ADInstruments, Sydney, Australia) for isometric tension recording (PowerLab, ADInstruments) and allowed to equilibrate at optimal basal tension (2.0 g; determined in preliminary experiments; data not shown). The rings were exposed to 60 mM potassium chloride twice before the actual experiment. The resulting increase in tension was used as a reference contraction. The rings were then incubated with different antagonists or inhibitors for at least 40 min. Depending on the experiment, either no vasoconstrictor substance was added (quiescent preparations) or the rings were exposed to the thromboxane A 2/prostaglandin H2 receptor agonist 9,11-dideoxy-11␣,9␣-epoxymethanoprostaglandin F 2␣ (U-46619, 3 ϫ 10 Ϫ8 M) (3) until a sustained contraction with a magnitude of ϳ100% of the reference contraction to 60 mM KCl was obtained (contracted preparations).
Direct Effects of Secretoneurin
Quiescent or contracted preparations were exposed to secretoneurin in cumulative concentrations (10 Ϫ13 to 10 Ϫ6 M) to determine whether or not the peptide possesses acute contracting or relaxing effects.
Long-Term Effects Of Secretoneurin
In a first series of experiments, rings with endothelium were incubated for 3 h with secretoneurin (10 Ϫ12 or 10 Ϫ8 M) in control solution. The contracted preparations were exposed to cumulative increments of the calcium ionophore A-23187 (10 Ϫ9 to 10 Ϫ6 M), bradykinin (10 Ϫ10 to 10 Ϫ6 M), sodium nitroprusside (10 Ϫ8 to 10 Ϫ5 M), or isoproterenol (10 Ϫ9 to 10 Ϫ6 M). In another series of experiments, rings with endothelium were incubated for 24 h with secretoneurin (10 Ϫ12 or 10 Ϫ8 M) in control solution with 2% bovine serum albumin and 1% antibiotic-antimycotics (Invitrogen, Hong Kong, China) in a cell incubator aerated with 5% CO 2-95% room air at 37°C. The rings were then used for isometric tension recording. Contracted preparations were exposed to cumulative concentrations of sodium nitroprusside, calcium ionophore (A-23187), bradykinin, or isoproterenol, and quiescent preparations were exposed to U-46619.
Cell Culture
PCAEC line (Cell Applications, San Diego, CA) were cultured in Eagle's minimal essential medium-Earle's balanced salt solution (1:1) with 0.1 mM nonessential amino acids, 1 mM pyruvate, 15% fetal bovine serum, and 1% antibiotic-antimycotics (Invitrogen, Hong Kong, China) at 37°C with 5% CO2-95% room air.
The cells were incubated with vehicle or secretoneurin (10 Ϫ12 or 10 Ϫ8 M) for 24 h before stimulation with A-23187 (10 Ϫ7 M) for 5 min. They were then washed in ice-cold phosphate-buffered saline and kept at 4°C until measurements were made.
Protein Extraction and Immunoblotting
PCAECs were homogenized in lysis buffer containing 20 mM Tris · HCl, 1% Triton X-100, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 2.5 mM sodium pyrophosphate, 1 mM ␤-glycerophosphate, and 1 mM sodium orthocanadate with a mix of protease inhibitors consisting of 100 mM phenylmethylsulfonyl fluoride, 10 g/ml trypsin inhibitors, 1 mg/ml leupeptin, and 2 g/ml pepstatin A. The mixture was sonicated and then centrifuged at 5,000 rpm for 3 min at 4°C, and the supernatant was kept at Ϫ20°C until use. The protein concentration was determined spectrophotometrically using the Bradford protein assay reagent with bovine serum albumin as a standard. Tissue homogenate protein (40 g) were used. The samples were mixed with sample buffer with reducing agent and heated at 95°C for 10 min and then subsequently separated by SDS-PAGE (7.5%). The proteins were transferred electrophoretically onto nitrocellulose membranes. For eNOS dimerization ratio, the samples were only mixed with sample buffer with reducing agent but not heated and kept on ice until loaded onto the gel for electrophoresis. The membranes were then blocked in Tris-buffered saline with 0.5% Tween-20 (TBST) with 5% bovine serum albumin (5% BSA TBST), washed in TBST, and then incubated with primary antibodies overnight at 4°C, diluted with 5% BSA TBST in the following ratio: anti-calmodulin antibody (1:1,000; Abcam, Cambridge, MA), anti-phospho(ser1177)eNOS antibody (1:1,000; Cell Signaling Technology, Danvers, MA), or antieNOS antibody (1:1,000; Cell Signaling Technology). The membranes were then incubated with horseradish peroxidase-conjugated anti-mouse antibody (1:3,000 in 5% BSA TBST; GE Healthcare, Hong Kong, China) at room temperature for 2 h. For measurement of ␤-actin, the membranes were incubated with monoclonal ␤-actin antibody (1:5,000 in 5% BSA TBST; Sigma Chemicals) for 1 h at room temperature and then with horseradish peroxidase-conjugated anti-mouse antibodies (1:5,000). The computer package MultiAnalysis (Bio-Rad, Hercules, CA) was used to analyze the optical densities of the protein bands. The eNOS dimerization ratio is obtained by dividing the density of the eNOS dimer by that of the monomer. The expression of calmodulin and eNOS was presented as the density of the protein divided by that of ␤-actin. 
Calculations and Statistical Analysis
Contractions are expressed as the changes of tension in percentage of the reference response to 60 mM KCl. Relaxations are expressed as the decrease in tension in percentage of the contraction to U-46619. The results are presented as means Ϯ SE; n refers to the number of experimental animals. Statistical analysis was performed by two-way ANOVA. The results were analyzed and graphed by Excel 2007 (Microsoft, NY) or Prism (version 5; GraphPad Software, La Jolla, CA). P Ͻ 0.05 indicated statistically significant differences.
RESULTS
Isometric Tension Recordings
Direct effects. Secretoneurin did not cause contraction in quiescent preparations with or without endothelium (data not shown). However, in contracted preparations it caused a stable relaxation at 10 Ϫ7 M and a transient relaxation with the subsequent concentrations (Fig. 1, A-C) . The relaxation was observed only in rings with endothelium. The decrease in tension typically lasted from 40 s to 1 min (Fig. 1A) . The relaxation to secretoneurin was also observed in the first branches of the artery (Fig. 1B) .
The relaxation to secretoneurin was not affected by the combination of potassium channel inhibitors TRAM-34 plus UCL 1684 (4) . However, the concentration-relaxation curve showed a significant reduction in relaxation when the preparations were incubated with the nitric oxide synthase inhibitor L-NAME (10 Ϫ4 M). The relaxation to secretoneurin was abolished when the preparations were incubated with the combination of L-NAME plus indomethacin (10 Ϫ5 M) but was not significantly affected by indomethacin alone (Fig. 2) . Incubation with the G i protein inhibitor pertussis toxin (1 g/ml) did not significantly affect the relaxation to secretoneurin in preparations with endothelium (data not shown).
Long-term effects. Preparations were incubated with secretoneurin (10 Ϫ12 and 10 Ϫ8 M) for either 3 or 24 h, and their responses to A-23187, bradykinin, sodium nitroprusside, and isoproterenol were tested during contractions to U-46619. After 3 h of incubation with secretoneurin (10 Ϫ12 and 10 Ϫ8 M), there were no significant changes to the responses to A-23187, bradykinin, sodium nitroprusside, or isoproterenol in preparations contracted with U-46619 (data not shown). After 24 h of incubation with secretoneurin, the relaxation to A-23187 was significantly potentiated and, to the same extent, after incubation with 10 Ϫ12 (Fig. 3A) and 10 Ϫ8 M (data not shown) of the peptide. This potentiation was not observed in preparations incubated with the combination of secretoneurin plus L-NAME (10 Ϫ4 M) (Fig. 3A) . The calmodulin antagonist calmidazolium (10 Ϫ5 M) nearly abolished the relaxations to A-23187; in its presence, the incubation with secretoneurin no longer potentiated the response to the calcium ionophore (data not shown). The concentration-relaxation curves to bradykinin in the absence of inhibitors were not significantly different (data not shown), but in the presence of indomethacin (10 Ϫ5 M) plus TRAM-34 (10 Ϫ7 M) and UCL 1684 (10 Ϫ7 M), the relaxation was significantly augmented in preparations incubated with secretoneurin [10 Ϫ12 M (Fig. 3B ) and 10 Ϫ8 M (data not shown)] compared with control. Such potentiation was not observed in the presence of L-NAME (Fig. 3B ) or in preparations incubated with secretoneurin in the presence of indomethacin plus L-NAME (data not shown).
Relaxations to sodium nitroprusside (Fig. 4A ) and isoproterenol (data not shown), as well as the concentration-contraction curve to U-46619 (Fig. 4B) , were not significantly different in control preparations and in arteries incubated with secretoneurin. Ϫ8 M U-46619); n ϭ 6 -8 animals. #P Ͻ 0.001, L-NAME vs. ϩEC; *P Ͻ 0.05, L-NAME ϩ TRAM ϩ UCL vs. Indo ϩ TRAM ϩ UCL ϩ L-NAME.
Cell Culture Experiments
The eNOS expression in the PCAEC cultures was significantly increased by the incubation with secretoneurin (10 Ϫ12 or 10 Ϫ8 M; Fig. 5A ). The dimerization ratio of eNOS was significantly increased after stimulation with A-23187 (10 Ϫ7 M) compared with basal conditions. Incubation with secretoneurin did not affect the basal dimerization of eNOS, but when stimulated by A-23187, a significant increase was observed in the dimerization ratio compared with control (Fig. 5B) .
Incubation with secretoneurin (10 Ϫ12 or 10 Ϫ8 M) significantly augmented the protein presence of calmodulin in cultures of PCAECs (Fig. 6 ).
DISCUSSION
The current study reveals a novel effect of secretoneurin in vascular tissue besides its proinflammatory (8, 11, 34) and proangiogenic properties (14) . Indeed, high concentrations of the peptide caused endothelium-dependent relaxations of porcine coronary arteries. These relaxations must involve the activation of eNOS leading to the production of nitric oxide, since they are reduced by L-NAME, the inhibitor of the enzyme (15) . Endothelium-dependent relaxations to endogenous substances are mediated by either G i (e.g., ␣ 2 -adrenergic agonists, serotonin)-or G q (e.g., bradykinin, adenine nucleotides)-coupling proteins (6) . The lack of effect of pertussis toxin observed in the present experiments implies that the response to secretoneurin does not depend on G i proteins. Endotheliumdependent relaxations can also involve the activation of cyclooxygenase, presumably leading to the production of prostacyclin (21) . This appears to be, in part, the case for the response to secretoneurin. However, it is preferentially caused by the nitric oxide pathway, because the presence of nitric oxide synthase inhibitor (L-NAME) reduced the relaxation to a large extent, and only then did the relaxations depend on cyclooxygenase. The latter conclusion is prompted by the lack of effects on the relaxation when the preparations were incubated with indomethacin alone and by its abolition after incubation with the combination of L-NAME plus indomethacin (4) . A similar pattern of interaction has been observed in the rabbit mesenteric artery, where an inhibitor of phospholipase A 2 (the enzyme that yields arachidonic acid for further metabolism by cyclooxygenase) does not reduce relaxations to acetylcholine except in the presence of a nitric oxide synthase inhibitor (9) . The fact that indomethacin alone did not reduce this relaxation could be due to the efficacy/potency of nitric oxide in inhibiting contractions of vascular smooth muscle, which masks the weaker effects of the vasodilators produced by cyclooxygenase. Alternatively, nitric oxide may inhibit cyclooxygenase as it does in the rat aorta (30) .
The release of endothelium-derived hyperpolarizing factor (EDHF) contributes to endothelium-dependent relaxations of coronary arteries (20, 24) . However, EDHF-mediated responses do not contribute to the response to secretoneurin to judge from the lack of effects of the combination of TRAM-34 and UCL 1684, which abrogates endothelium-dependent hyperpolarizations (4).
Whether or not the relaxations observed with secretoneurin in the present study play a role in physiology or pathophysiology is unknown at this stage. In humans, immunoreactivity of the peptide has been demonstrated in several tissues including the pituitary and the pancreas (35) . When infused into the brain, secretoneurin stimulates dopamine release from striatal neurons and the basal ganglia, suggesting a role in the neuroendocrine system (35) . The protein is constitutively expressed in the adrenal medulla, spinal cord, brain, and ileum (5) . The expression of secretoneurin is increased under pathological conditions such as tumoral growth and hypoxia (5, 31) , and it has been used clinically as a marker for the presence of tumors since its plasma concentration in patients with cancer ranges from 58.3 Ϯ 8.1 to 410 Ϯ 113.9 compared with the 22.1 Ϯ 1.1 fmol/ml levels in healthy subjects (10, 28) . The concentrations (10 Ϫ7 to 10 Ϫ6 M) with which relaxations to secretoneurin were observed in the present study are larger than the plasma levels reached in humans, even in patients (10, 28 ). However, the plasma level may not reflect the exact local concentration in the vicinity of the endothelium in vivo.
Secretoneurin is upregulated in senescent-cultured endothelial cells by as much as 48-fold (17) . After in vivo regeneration of the endothelium, the G i -mediated nitric oxide-dependent relaxations are lost due a loss of function of those G proteins (26, 27) . Although the transendothelial migration signaling by secretoneurin is prevented by pertussis toxin, a G i protein antagonist, suggesting the involvement of these coupling proteins in the response of the endothelium to the peptide (12) , the present results demonstrate that the endothelium-dependent relaxation to secretoneurin cannot depend on G i protein coupling since it is not inhibited by the toxin. The present experiments showing that secretoneurin can activate eNOS in a G i -independent manner may suggest that an upregulation of the presence of the peptide could be a compensatory consequence to the loss of G i -mediated nitric oxide-dependent responses in regenerated endothelium (11, 26, 27) .
The concentrations of secretoneurin that are found in the plasma of normal healthy subjects possess proinflammatory activities (5, 8, 10, 28) . In attempt to mimic the in vivo conditions, preparations were incubated with secretoneurin for prolonged periods (3 or 24 h ). This prolonged incubations did not affect relaxations of the coronary arterial smooth muscle whether due to the production of cGMP (sodium nitroprusside) or cAMP (isoproterenol). In terms of endothelium-dependent relaxations, the response to the calcium ionophore A-23187 was augmented in preparations treated with secretoneurin for 24 h. The effect of the two concentrations tested was compa- rable, indicating that a maximal effect had already been reached at 10 Ϫ12 M. The potentiation was prevented by the simultaneous incubation with L-NAME and, hence, by the lack of activity of eNOS (25) . Indeed, although A-23187 can evoke endothelium-dependent hyperpolarizations (24) , the potentiation of the response to A-23187 cannot be attributed to an increased production of EDHF in the preparations treated with secretoneurin, because L-NAME alone was sufficient to abolish the difference in relaxation. A similar conclusion can be reached when analyzing the response to bradykinin. Indeed, in preparations treated with indomethacin, TRAM-34 and UCL 1684 [to inhibit both cyclooxygenase and EDHF-dependent responses, leaving only the nitric oxide pathway active (4)] incubation with secretoneurin augmented the relaxation to the kinin. This potentiation was also absent in the presence of L-NAME, which is in agreement with the relaxation observed with A-23187. Although bradykinin can release EDHF (24) , no potentiation of the response to the kinin was evoked by secretoneurin under conditions [incubation with indomethacin plus L-NAME, where only EDHF-mediated endothelium-dependent relaxations are possible (4)]. These findings suggest, as for A-23187, that the augmented response involves solely an enhanced activity of eNOS pathway. This conclusion is supported by the Western blot results. Indeed, the expression of eNOS was augmented to the same extent after incubation with both concentrations of secretoneurin tested. Furthermore, the dimerization of eNOS was increased after stimulation with A-23187 by the incubation with secretoneurin compared with control, suggesting that the peptide favors the presence of dimers, the active state, of the enzyme (7).
The signal transduction of eNOS is mainly calcium/calmodulin dependent. When there is a rise in intracellular calcium [following stimulation of endothelial cell membrane receptors (e.g., with bradykinin) or facilitation of calcium entry (with A-23187)], the calcium/calmodulin complex is formed, which subsequently binds to eNOS and is responsible for the activation of the enzyme and consequently leads to dimerization (7) . The present results demonstrate that secretoneurin augments the expression of calmodulin in PCAECs, which can in part explain an increased activation of eNOS. Taken in conjunction with the observation that the potentiation exerted by secretoneurin is absent in the presence of calmidazolium (23) , the present findings suggest that the enhanced relaxation caused by the peptide is due to the combined effects of increased levels of calmodulin binding to calcium [that would lead to more activation (dimerization)] and the larger amounts of eNOS.
Besides its endocrine functions (35) , proinflammatory properties (11, 12, 34) , and possible involvement in neurological activities (31) , the present study reveals a potential role of secretoneurin in the endothelium-dependent control of vascular tone. The protein may play a compensatory role in this regard. In regenerated and senescent endothelium, the reduced responsiveness to activation of endothelial G i -coupled receptors (27) and the reduced eNOS level (16) reduce the capacity for endothelium-dependent vasodilatation (2, 33) ; (29) . The augmented presence of secretoneurin could enhance endotheliumdependent relaxations due to activation or increased expression of the endothelial nitric oxide synthase pathway by non-G idependent mechanisms [e.g., in response to endogenous bradykinin (19) ].
